8-K - Vycor Medical, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Vycor Medical reported annual revenue growth of 17% to $1.86 million for 2025, achieving an operating profit of $33,900 compared to a loss in 2024, driven by strong international sales of its neurosurgical device.

Key Takeaways

1Revenue increased 17% to $1.86 million in 2025, with the Vycor Medical division growing 18% primarily from international markets.

2The company achieved GAAP operating profit of $33,900, reversing a $9,145 loss in 2024, while non-GAAP operating profit was $145,881.

3Gross margin declined to 83% from 89% due to validation, shipping, higher manufacturing costs, and increased international sales mix.

4Seven new peer-reviewed studies on the ViewSite Brain Access System were published in 2025, bringing total clinical papers to 50.

5A new study validated NovaVision's NeuroEyeCoach therapy as equally effective in home and clinic settings, supporting digital healthcare trends.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by referenc

Financial Results

9.01

. Financial Statements and Exhibits. ** (d) Exhibits. | Exhibit 99.1. | | Vycor Medical, Inc. Press Release dated March 31, 2026. | |---|---|---| | 104 | | Cove

Exhibits Only

Source Document

Results of Operations

Year ended December 31, 2025

Metric	Value	Basis	Prior Period
Revenue	$1.9M	GAAP	$1.6M
Gross Profit	$1.6M	GAAP	$1.4M
Operating Profit	$33.9K	GAAP	$-9.1K
Net Loss	$-72.4K	GAAP	$-107.2K
Loss Per Share	$-0.01	GAAP	$-0.01
Non-GAAP Operating Profit	$145.9K	Non-GAAP	$81.5K
Non-GAAP Net Loss	$-284.8K	Non-GAAP	$-340.9K

Exhibits (2)

8-K

99.1

EX-99.1